Meaghan Dendy
Icahn School of Medicine at Mount Sinai
3 Papers
Meaghan Dendy is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & PTEN. The author has an hindex of 3, co-authored 3 publications. Previous affiliations of Meaghan Dendy include Columbia University Medical Center.
Chat about Author
Papers
A secreted PTEN phosphatase that enters cells to alter signaling and survival.
Benjamin D. Hopkins,Barry Fine,Nicole Steinbach,Nicole Steinbach,Meaghan Dendy,Zachary Rapp,Jacquelyn Shaw,Jacquelyn Shaw,Kyrie Pappas,Kyrie Pappas,Jennifer S. Yu,Cindy Hodakoski,Sarah M. Mense,Joshua U. Klein,Joshua U. Klein,Sarah Pegno,Maria Luisa Sulis,Maria Luisa Sulis,Hannah E. Goldstein,Hannah E. Goldstein,Benjamin Amendolara,Benjamin Amendolara,Liang Lei,Liang Lei,Matthew Maurer,Matthew Maurer,Jeffrey N. Bruce,Peter Canoll,Peter Canoll,Hanina Hibshoosh,Hanina Hibshoosh,Ramon Parsons +31 more
TL;DR: A 576–amino acid translational variant of PTEN, termed PTEN-Long, that arises from an alternative translation start site 519 base pairs upstream of the ATG initiation sequence, adding 173 N-terminal amino acids to the normal PTEN open reading frame may have therapeutic uses.
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Qing-Bai She,Qing-Bai She,Sofia K. Gruvberger-Saal,Sofia K. Gruvberger-Saal,Matthew Maurer,Yilun Chen,Mervi Jumppanen,Tao Su,Meaghan Dendy,Ying Ka Ingar Lau,Lorenzo Memeo,Hugo M. Horlings,Marc J. van de Vijver,Jorma Isola,Hanina Hibshoosh,Neal Rosen,Ramon Parsons,Lao H. Saal,Lao H. Saal +18 more
TL;DR: This study emphasizes the importance of PI3K/PTEN pathway activity in ER-negative and basal-like breast cancer and supports the future clinical evaluation of combining EGFR andPI3K pathway inhibitors for the treatment of BLBC.
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
Elias E. Stratikopoulos,Meaghan Dendy,Matthias Szabolcs,Alan J. Khaykin,Celine Lefebvre,Ming-Ming Zhou,Ramon Parsons +6 more
TL;DR: Resistance to a class I PI3K inhibitor was associated with feedback activation of tyrosine kinase receptors, AKT, mTOR, and MYC and inhibitors of bromodomain and extra terminal domain proteins failed to affect tumor growth.
237